CTGTAC endorsed that single-arm Ignyte response rate and durability support clinically meaningful systemic antitumor activity attributable to intratumoral RP1 combined with nivolumab in ...
Vogenx estimates net proceeds of approximately $67.8 million based on an assumed offering price of $12.00 per share. 3 Vogenx is a clinical-stage biopharmaceutical company focused on disorders linked ...
Learn why reshoring and tariff exposure are accelerating the trend toward manufacturing in the market where a product is sold. Understand the significance of the Section 301 investigation into Germany ...
Two-thirds of pharmaceutical product launches fail to meet first-year commercial expectations, and the gap between launch strategy and field execution is almost always why, according to this ...
Two-thirds of pharmaceutical product launches fail to meet first-year commercial expectations, and the gap between launch strategy and field execution is almost always why, according to this ...
Understand how patient advocacy groups are weighing MFN's affordability promise against other access issues like Medicaid community engagement requirements. Learn why international reference pricing ...
Pharmaceutical Executive spoke with John Standford, executive director of Incubate, about the rise of China as an R&D partner and the US government’s responses. According to him, years of investment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results